Wt1 peptide vaccine for the treatment of cancer

Document Outline

• WT1 peptide vaccine for the treatment of cancer
  • Introduction
  • Identification of WT1 protein-derived CTL epitopes and in vitro generation of WT1-specific CTLs
  • Spontaneous immune responses against WT1 protein in cancer patients
  • Mouse in vivo models for WT1 peptide cancer vaccine
  • Clinical trials of WT1 peptide cancer vaccine
    • Clinical responses
      • Patients with myeloid malignancies, including AML and MDS
      • Patients with multiple myeloma (MM)
      • Patients with MDS, vaccinated with ‘very low dose’ of WT1 peptide
      • Patients with solid cancer
      • No damage to normal tissues by WT1 peptide vaccination
      • Immunological responses and their correlation with clinical responses
  • Perspectives
    • New target diseases for WT1-directed cancer immunotherapy
    • Enhancement of clinical efficacy and usefulness of WT1 peptide vaccine
    • Translational research and reverse-translational research
    • Evaluation of cancer vaccine-induced clinical responses
    • Appropriate clinical settings for cancer vaccine
  • Conclusion
  • Acknowledgements
  • References and recommended reading